CPC Biotech Debuts Unified Bioprocess Fluid Portfolio

Why It Matters

The consolidation creates a one‑stop supplier for critical fluid‑handling components, accelerating time‑to‑market for biologics and reducing supply‑chain complexity for biopharma firms.

Key Takeaways

• CPC Biotech unites CPC connectors with PSG pumps, meters, sensors.
• Portfolio spans connectors, low-shear pumps, flow meters, sensors.
• Serves biopharma, cell therapy, and gene therapy manufacturers.
• Manufactured across North America, Europe, Asia; sold in 50+ countries.
• Launch showcased at INTERPHEX 2026, Booth #3129, New York.

Pulse Analysis

Fluid management is a linchpin of modern biomanufacturing, where precision, sterility, and reliability directly affect product yield and regulatory compliance. As biologics, cell therapies, and gene therapies move from discovery to commercial scale, manufacturers demand integrated solutions that minimize contamination risk and streamline validation. The market has seen a proliferation of niche component suppliers, creating fragmented supply chains that can delay projects and increase costs. Consolidating expertise under a single brand addresses these challenges by offering end‑to‑end fluid path control, from sterile connections to accurate flow measurement.

CPC Biotech’s launch merges CPC’s decades‑long reputation for single‑use sterile connectors with PSG Biotech’s proven low‑shear pumps and high‑accuracy flow meters. The combined portfolio covers the entire fluid path—connect, move, and measure—enabling customers to source all critical components from one trusted partner. This integration not only simplifies procurement but also facilitates coordinated engineering, where connector geometry and pump dynamics are co‑optimized for delicate biologics. With manufacturing facilities on three continents and a channel network in over 50 countries, the brand can deliver consistent quality and rapid support to global biopharma operations.

The debut at INTERPHEX 2026 positions CPC Biotech at the forefront of industry dialogue, offering live demonstrations that highlight the seamless interoperability of its products. For biopharma firms, the promise of reduced downtime, lower validation effort, and improved process scalability translates into faster clinical timelines and lower cost of goods. As the sector continues its rapid expansion—driven by personalized medicines and advanced therapies—companies that provide integrated fluid‑management solutions are likely to capture a growing share of the market, reinforcing Dover’s strategic foothold in the bioprocessing ecosystem.